{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.69","upperLimit":"8.38","value":"4.17"},{"comment":"Upper limit not calculated due to insufficient number of events","groupId":"OG001","lowerLimit":"5.85","upperLimit":"NA","value":"11.14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"526"},{"groupId":"OG001","value":"264"}],"units":"Participants"}],"description":"Duration of treatment is an investigator-assessed outcome of next-line therapy (NLT) defined as the time from first dose date of NLT to last dose date of NLT. Participants who did not stop the NLT were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 480 mg IV Nivolumab in an approximately 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. Participants began study treatment (Cycle 1) within 3 calendar days of randomization. Subsequent cycles were initiated within ± 3 days of the target visit date.","id":"OG000","title":"Nivolumab"},{"description":"Nivolumab matched placebo (0.9% Sodium Chloride for Injection/5% Dextrose for Injection) IV in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, withdrawal of consent, completion of 12 months of treatment (from first dose of study treatment), disease recurrence, or the study ends, whichever occurred first. In the event of disease recurrence, participants on the blinded nivolumab or placebo portion will be offered the option to receive open-label on-protocol nivolumab treatment. Participants received 480 mg IV Nivolumab in a 30-minute infusion on Day 1 of each 4-week treatment cycle until unacceptable toxicity, recurrence/progression, withdrawal of consent, completion of 12 months of treatment from first dose of open-label study treatment, whichever occurred first.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From first dose date of next-line therapy to last dose date of next-line therapy (up to approximately 32 months)","title":"Duration of Treatment on Next Line Therapy Per Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Months"}